{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:34:14Z","timestamp":1788885254934,"version":"build-2803163510"},"reference-count":43,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Etrasimod and ozanimod are selective sphingosine 1-phosphate receptor modulators targeting the S1P\n            <jats:sub>1,4,5<\/jats:sub>\n            , and S1P\n            <jats:sub>1,5<\/jats:sub>\n            receptors, respectively, for the treatment of patients with moderately to severely active ulcerative colitis (UC). No head-to-head trial data exist between the two treatments. We compared these treatments indirectly using key efficacy outcomes from pivotal trials with induction and maintenance phase data adjusting for differences in clinical trial design and populations.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Individual patient data for etrasimod were matched to published aggregate data of ozanimod by key baseline characteristics. An anchored matching-adjusted indirect comparison (MAIC) was conducted for the induction period. An unanchored MAIC was utilized during the maintenance period due to differences in placebo arms between trials as a result of differing trial designs. Matching characteristics measured at baseline were age, sex, corticosteroid use, duration of UC, biologic exposure, modified Mayo score, and presence of left-sided colitis. Outcomes were clinical response and clinical remission for the induction period, and clinical response and clinical remission among induction phase responders for the maintenance period. Two sensitivity analyses were conducted. The first matched on prior TNFi exposure rather than biologic exposure, the second sensitivity analysis included an induction only etrasimod trial (ELEVATE UC 12).\n            <jats:bold>Results:<\/jats:bold>\n            There were no significant differences between etrasimod and ozanimod at the end of the induction period for clinical response and clinical remission, respectively (relative risk [RR] 0.98 [95% confidence interval (CI): 0.76\u20131.33], RR: 1.25 [95% CI: 0.71\u20132.92]). At the end of maintenance, etrasimod demonstrated improved outcomes compared with ozanimod for both clinical response (RR: 1.18 [95% CI: 1.05\u20131.30]) and clinical remission among induction phase responders (RR: 1.33 [95% CI: 1.12\u20131.55]). In the sensitivity analysis that matched on prior TNFi exposure rather than biologic exposure, there were no notable differences compared with the primary analyses. In the sensitivity analysis pooling ELEVATE UC 12 and ELEVATE UC 52 data, results were similar for clinical response (RR: 0.90 [95% CI: 0.75\u20131.10]) but etrasimod showed reduced efficacy for clinical remission (RR: 0.72 [95% CI: 0.50\u20131.12]) compared with the primary analysis, though overall remained not significantly different from ozanimod.\n            <jats:bold>Conclusion:<\/jats:bold>\n            MAIC results suggest that patients receiving etrasimod have similar induction results but are more likely to have clinical response and clinical remission at the end of the maintenance phase compared with patients receiving ozanimod. Despite the approach to ensure similarity between the trials by weighting, residual imbalance is possible, and results should be interpreted in the context of the assumptions.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0193","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T09:46:37Z","timestamp":1740390397000},"source":"Crossref","is-referenced-by-count":5,"title":["Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"first","affiliation":[{"name":"Department of Medicine &amp; Department of Epidemiology &amp; Biostatistics, Western University, London, ON, N6G 2M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5855-9873","authenticated-orcid":false,"given":"Tim","family":"Raine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Addenbrooke\u2019s Hospital, Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-6224","authenticated-orcid":false,"given":"Thomas P","family":"Leahy","sequence":"additional","affiliation":[{"name":"Putnam Associates LLC, Toronto, ON, M5V 3T5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-2659","authenticated-orcid":false,"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[{"name":"Putnam Associates LLC, New York, NY 10282, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7233-0933","authenticated-orcid":false,"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Pfizer Canada, Kirkland, QC, H9J 2M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":false,"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY 10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Bartolome","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY 10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1572-0241.2006.01000.x","article-title":"Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies","volume":"102","author":"Jess T","year":"2007","unstructured":"Jess T, Gamborg M, Munkholm P, S\u00f8rensen TI. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am. J. Gastroenterol. 102(3), 609\u2013617 (2007).","journal-title":"Am. J. Gastroenterol."},{"issue":"10080","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro R","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J. Ulcerative colitis. Lancet 389(10080), 1756\u20131770 (2017).","journal-title":"Lancet"},{"issue":"10401","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Berre C","year":"2023","unstructured":"Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet 402(10401), 571\u2013584 (2023).","journal-title":"Lancet"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484"},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine T","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J. Crohns. Colitis 16(1), 2\u201317 (2022).","journal-title":"J. Crohns. Colitis"},{"issue":"5","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner D","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160(5), 1570\u20131583 (2021).","journal-title":"Gastroenterology"},{"key":"e_1_3_8_9_2","unstructured":"National Institute for Health and Care Excellence. Ulcerative Colitis: management. NICE guideline [NG130] (2019). Available at: https:\/\/www.nice.org.uk\/guidance\/ng130"},{"key":"e_1_3_8_10_2","unstructured":"National Institute for Health and Care Excellence. Infliximab adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. Technology appraisal guidance [TA329] (2015). Available at: https:\/\/www.nice.org.uk\/guidance\/ta329"},{"key":"e_1_3_8_11_2","unstructured":"National Institute for Health and Care Excellence. Ustekinumab for treating moderately to severely active ulcerative colitis. Technology appraisal guidance [TA633] (2020). Available at: https:\/\/www.nice.org.uk\/guidance\/ta633"},{"key":"e_1_3_8_12_2","unstructured":"European Medicines Agency. Omvoh: EPAR \u2013 Product information. 2024. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omvoh-epar-product-information_en.pdf"},{"key":"e_1_3_8_13_2","unstructured":"Food & Drug Administration. Highlights of prescribing information: omvoh. 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761279s000lbl.pdf"},{"key":"e_1_3_8_14_2","unstructured":"National Institute for Health and Care Excellence. Vedolizumab for treating moderately to severely active ulcerative colitis. Technology appraisal guidance [TA342] (2015). Available at: https:\/\/www.nice.org.uk\/guidance\/ta342"},{"key":"e_1_3_8_15_2","unstructured":"National Institute for Health and Care Excellence. Tofacitinib for moderately to severely active ulcerative colitis. Technology appraisal guidance [TA547] (2018). Available at: https:\/\/www.nice.org.uk\/guidance\/ta547"},{"key":"e_1_3_8_16_2","unstructured":"National Institute for Health and Care Excellence. Filgotinib for treating moderately to severely active ulcerative colitis. Technology appraisal guidance [TA792] (2022). Available at: https:\/\/www.nice.org.uk\/guidance\/ta792"},{"key":"e_1_3_8_17_2","unstructured":"National Institute for Health and Care Excellence. Upadacitinib for treating moderately to severely active ulcerative colitis. Technology appraisal guidance [TA856] (2023). Available at: https:\/\/www.nice.org.uk\/guidance\/ta856"},{"key":"e_1_3_8_18_2","unstructured":"National Institute for Health and Care Excellence. Ozanimod for treating moderately to severely active ulcerative colitis. Technology appraisal guidance [TA828] (2022). Available at: https:\/\/www.nice.org.uk\/guidance\/ta828"},{"key":"e_1_3_8_19_2","unstructured":"National Institute for Health and Care Excellence. Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. Technology appraisal guidance [TA956] (2024). Available at: https:\/\/www.nice.org.uk\/guidance\/ta956"},{"issue":"15","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis","volume":"12","author":"Bencardino S","year":"2023","unstructured":"Bencardino S, D'Amico F, Faggiani I Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis. J. Clin. Med. 12(15), 5014 (2023).","journal-title":"J. Clin. Med."},{"issue":"9","key":"e_1_3_8_21_2","first-page":"761","article-title":"Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment \u2013 insights from phase II and III trials","volume":"59","author":"Massironi S","year":"2024","unstructured":"Massironi S, Furfaro F, Bencardino S, Allocca M, Danese S. Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment \u2013 insights from phase II and III trials. Gastroenterology 59(9), 761\u2013787 (2024).","journal-title":"Gastroenterology"},{"issue":"9","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00535-024-02130-x","article-title":"Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment \u2013 insights from phase II and III trials","volume":"59","author":"Massironi S","year":"2024","unstructured":"Massironi S, Furfaro F, Bencardino S, Allocca M, Danese S. Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment \u2013 insights from phase II and III trials. J. Gastroenterol. 59(9), 761\u2013787 (2024).","journal-title":"J. Gastroenterol."},{"issue":"1","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"i1576","DOI":"10.1093\/ecco-jcc\/jjad212.0979","article-title":"P849 Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis na\u00efve to advanced therapy","volume":"18","author":"Jairath V","year":"2024","unstructured":"Jairath V, Leahy T, Potluri R P849 Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis na\u00efve to advanced therapy. J. Crohns. Colitis 18(Suppl. 1), i1576\u2013i1577 (2024).","journal-title":"J. Crohns. Colitis"},{"issue":"5","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/MEG.0000000000002751","article-title":"Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis","volume":"36","author":"Rokkas T","year":"2024","unstructured":"Rokkas T, Gisbert JP, Ekmektzoglou K Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis. Eur. J. Gastroenterol. Hepatol. 36(5), 520\u2013533 (2024).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"5","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jrsm.1700","article-title":"Twenty years of network meta-analysis: continuing controversies and recent developments","volume":"15","author":"Ades A","year":"2024","unstructured":"Ades A, Welton NJ, Dias S, Phillippo DM, Caldwell DM. Twenty years of network meta-analysis: continuing controversies and recent developments. Res. Synth. Methods 15(5), 702\u2013727 (2024).","journal-title":"Res. Synth. Methods"},{"key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br. Med. J. 372, n71 (2021).","journal-title":"Br. Med. J."},{"issue":"14","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn WJ","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D'Haens G Ozanimod as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 385(14), 1280\u20131291 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10383","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase III studies","volume":"401","author":"Sandborn WJ","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase III studies. Lancet 401(10383), 1159\u20131171 (2023).","journal-title":"Lancet"},{"key":"e_1_3_8_29_2","article-title":"Ulcerative colitis: developing drugs for treatment","author":"Food & Drug Administration","year":"2022","unstructured":"Food & Drug Administration. Ulcerative colitis: developing drugs for treatment. Guidance for Industry (2022). Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ulcerative-colitis-developing-drugs-treatment","journal-title":"Guidance for Industry"},{"key":"e_1_3_8_30_2","unstructured":"Phillippo D Ades T Dias S NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (2016). Available at: https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-18-methods-for-population-adj"},{"key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.14309\/01.ajg.0000776308.71765.85","article-title":"S694: comparative efficacy and safety of ozanimod vs adalimumab and vedolizumab in patients with moderately to severely active ulcerative colitis","volume":"116","author":"Dubinsky MC","year":"2021","unstructured":"Dubinsky MC, Betts KA, LaPensee K S694: comparative efficacy and safety of ozanimod vs adalimumab and vedolizumab in patients with moderately to severely active ulcerative colitis. Am. J. Gastroenterol. 116, S314 (2021).","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jjac122","article-title":"Corticosteroid-sparing effects of filgotinib in moderately to severely active ulcerative colitis: data from the phase IIb\/III SELECTION study","volume":"17","author":"Loftus EV","year":"2023","unstructured":"Loftus EV, Vermeire S, Feagan BG Corticosteroid-sparing effects of filgotinib in moderately to severely active ulcerative colitis: data from the phase IIb\/III SELECTION study. J. Crohns. Colitis 17(2), 211\u2013220 (2023).","journal-title":"J. Crohns. Colitis"},{"issue":"7","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1016\/j.jval.2022.04.191","article-title":"CO95 a matching-adjusted indirect comparison of filgotinib versus tofacitinib for moderately to severely active ulcerative colitis","volume":"25","author":"Lu X","year":"2022","unstructured":"Lu X, Gray E, Xin Y CO95 a matching-adjusted indirect comparison of filgotinib versus tofacitinib for moderately to severely active ulcerative colitis. Value Health 25(7), S321 (2022).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"i785","DOI":"10.1093\/ecco-jcc\/jjac190.0788","article-title":"P658: comparative efficacy and safety of upadacitinib versus tofacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: a matching-adjusted indirect comparison","volume":"17","author":"Reinisch W","year":"2023","unstructured":"Reinisch W, Tran J, Patel K P658: comparative efficacy and safety of upadacitinib versus tofacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: a matching-adjusted indirect comparison. J. Crohns. Colitis 17(Suppl. 1), i785\u2013i786 (2023).","journal-title":"J. Crohns. Colitis"},{"issue":"6","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"issue":"10","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch JE","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28(10), 935\u2013945 (2010).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_8_37_2","unstructured":"Young R. MAIC: matching-adjusted indirect comparison. (2022). Available at: https:\/\/CRANR-project.org\/package=maic"},{"key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.14309\/01.ajg.0000592372.31005.a4","article-title":"709: optimizing the definition of clinical response using the modified Mayo score: an analysis of a phase 2 study with mirikizumab in patients with ulcerative colitis","volume":"114","author":"Jairath V","year":"2019","unstructured":"Jairath V, Sandborn WJ, Dong Y 709: optimizing the definition of clinical response using the modified Mayo score: an analysis of a phase 2 study with mirikizumab in patients with ulcerative colitis. Am. J. Gastroenterol. 114(Suppl.), S417 (2019).","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab M","year":"2025","unstructured":"Shehab M, Alrashed F, Alsayegh A Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis. Clin. Gastroenterol. Hepatol. 23(2), 250\u2013262 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","volume":"17","author":"Solitano V","year":"2023","unstructured":"Solitano V, Vuyyuru SK, MacDonald JK Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis. J. Crohns. Colitis 17(11), 1800\u20131816 (2023).","journal-title":"J. Crohns. Colitis"},{"issue":"10","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.cgh.2020.10.016","article-title":"Network meta-analysis of ulcerative colitis pharmacotherapies: carryover effects from induction and bias of the results","volume":"19","author":"Naessens D","year":"2021","unstructured":"Naessens D, Cameron C, Hoaglin DC. Network meta-analysis of ulcerative colitis pharmacotherapies: carryover effects from induction and bias of the results. Clin. Gastroenterol. Hepatol. 19(10), 2219\u20132221 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","article-title":"External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?","volume":"9","author":"Beyer-Westendorf J","year":"2011","unstructured":"Beyer-Westendorf J, B\u00fcller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J. Thromb. Haemost. 9(11), 2153\u20132158 (2011).","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/03007995.2019.1580094","article-title":"Treatment sequence network meta-analysis in Crohn's disease: a methodological case study","volume":"35","author":"Varu A","year":"2019","unstructured":"Varu A, Wilson FR, Dyrda P Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. Curr. Med. Res. Opin. 35(5), 733\u2013756 (2019).","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/03007995.2019.1580094","article-title":"Treatment sequence network meta-analysis in Crohn's disease: a methodological case study","volume":"35","author":"Varu A","year":"2019","unstructured":"Varu A, Wilson FR, Dyrda P Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. Curr. Med. Res. Opin. 35(5), 733\u2013756 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"1420455","DOI":"10.3389\/fphar.2024.1420455","article-title":"Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Qiu J","year":"2024","unstructured":"Qiu J, Liu J, Cai K Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 15, 1420455 (2024).","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T11:45:35Z","timestamp":1742557535000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.57264\/cer-2024-0193"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0193","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"article-number":"e240193"}}